Zim Laboratories opens remote e-voting for director pay revision

2 min read     Updated on 14 Jul 2026, 04:42 PM
scanx
Reviewed by
Ashish TScanX News Team
AI Summary

Zim Laboratories Limited has initiated the remote e-voting process to seek shareholder approval for revising the remuneration structure of its Managing Director and Whole-Time Director. The postal ballot notice was dispatched on July 10, 2026, and the company has submitted the newspaper publication details to the exchanges. The proposed remuneration includes a fixed pay of up to ₹3.00 crore for the Managing Director and ₹2.50 crore for the Whole-Time Director, along with performance-linked incentives. The voting period is scheduled from July 13, 2026, to August 11, 2026.

powered bylight_fuzz_icon
45241585

*this image is generated using AI for illustrative purposes only.

Zim Laboratories Limited has opened remote e-voting for shareholders to approve the revision of remuneration for its Managing Director and Whole-Time Director. The postal ballot notice was dispatched on July 10, 2026, via email to members registered as on the cut-off date of July 3, 2026. The company has submitted the newspaper publication details regarding this notice to the stock exchanges.

The special resolutions propose a fixed remuneration of up to ₹3.00 crore per annum for Dr. Anwar Daud, Managing Director, and up to ₹2.50 crore per annum for Mr. Zulfiquar Kamal, Whole-Time Director. Additionally, the Managing Director is eligible for a Performance Linked Incentive (PLI) of up to 42.50% of the aggregate fixed salary, while the Whole-Time Director is eligible for a PLI of up to 25% of the aggregate fixed salary. These revisions are proposed to be effective until the expiry of their current terms, which are July 30, 2027, and October 18, 2027, respectively.

Remuneration Details

The following table outlines the proposed remuneration structure for the directors:

Director Position Fixed Remuneration (Per Annum) Performance Linked Incentive Term Expiry
Dr. Anwar Daud Managing Director Up to ₹3.00 crore Up to 42.50% of fixed salary July 30, 2027
Mr. Zulfiquar Kamal Whole-Time Director Up to ₹2.50 crore Up to 25% of fixed salary October 18, 2027

The company states that the revisions are intended to simplify the remuneration structure by removing lower limits while retaining the maximum limits. The Nomination and Remuneration Committee and the Board of Directors have approved the revised methodology for determining the performance-linked incentives to ensure greater consistency and transparency.

Voting Process and Timelines

The remote e-voting period commences at 9:00 a.m. IST on July 13, 2026, and concludes at 5:00 p.m. IST on August 11, 2026. The facility is being provided by National Securities Depository Limited (NSDL). Members whose names appear in the Register of Members or Register of Beneficial Owners as on July 3, 2026, the cut-off date, are eligible to vote. The notice has been dispatched electronically to members, and physical ballot forms will not be accepted.

Ms. Roshni Jethani, a Practicing Company Secretary, has been appointed as the Scrutinizer to oversee the postal ballot process. The results of the voting will be announced within two working days from the conclusion of remote e-voting. The resolutions, if passed by the requisite majority, will be deemed to have been passed on the last date of e-voting, August 11, 2026. The company will intimate the results to BSE Limited and National Stock Exchange of India Limited and upload them to its website.

Historical Stock Returns for Zim Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
0.0%-6.18%-10.08%+55.90%-0.18%-0.56%

What specific performance metrics will be utilized to determine the eligibility for the Performance Linked Incentives?

How will the market react to the significant increase in the Managing Director's potential total compensation package?

Will the company disclose the detailed rationale behind the specific remuneration caps to ensure shareholder transparency?

Zim Laboratories to meet Canara HSBC Life Insurance on July 3

0 min read     Updated on 01 Jul 2026, 05:41 PM
scanx
Reviewed by
Ashish TScanX News Team
AI Summary

Zim Laboratories Ltd has scheduled a one-on-one meeting with Canara HSBC Life Insurance on July 3, 2026, to discuss business matters. The in-person meeting is subject to change due to exigencies, and no unpublished price sensitive information will be shared. The disclosure was made to BSE Limited and National Stock Exchange of India Limited in compliance with Regulation 30 of the SEBI (LODR) Regulations, 2015.

powered bylight_fuzz_icon
44360675

*this image is generated using AI for illustrative purposes only.

Zim Laboratories Ltd has scheduled a meeting with investors and analysts for July 3, 2026. The company will hold a one-on-one session with Canara HSBC Life Insurance to discuss business matters. The meeting is scheduled to take place in person, providing an opportunity for direct engagement with the fund manager.

The disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that no unpublished price sensitive information (UPSI) will be shared during the aforesaid meeting. The schedule remains subject to change due to exigencies.

Meeting Schedule

Day and Date Name of Investors/ Analysts/Conference Type of Meeting
Friday, 03 July 2026 Canara HSBC Life Insurance In person/Physical (One to One)

The communication was addressed to the stock exchanges, including BSE Limited and National Stock Exchange of India Limited, to keep the intimation on record.

Historical Stock Returns for Zim Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
0.0%-6.18%-10.08%+55.90%-0.18%-0.56%

What specific strategic outcomes is Zim Laboratories aiming to achieve through this engagement with Canara HSBC Life Insurance?

Could this meeting signal a potential shift in Zim Laboratories' investor base or future capital raising plans?

How might the insights gained from this interaction influence Zim Laboratories' business strategy or operational focus in the coming fiscal year?

More News on Zim Laboratories

1 Year Returns:-0.18%